TScan Therapeutics, Inc. (TCRX) reported Q3 EPS of ($0.67), $0.05 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $3.36 million versus the consensus estimate of $3.66 million.
TScan Therapeutics, Inc. (TCRX) reported Q3 EPS of ($0.67), $0.05 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $3.36 million versus the consensus estimate of $3.66 million.